NVDA Is Coiled On The 191.23 Floor. The Daily Flipped Long.NVIDIA CorporationNASDAQ:NVDAvirDeStateraNVDA Is Coiled On The 191.23 Floor. The Daily Flipped Long. NVDA is sitting at 194.44, a couple dollars above the April floor at 191.23 that held for a third time this week. After two days of the daily selling accelerating into the floor, the longer-term read flipped sides at the level - it now points up for the first time since the decline began. But price hasn't gone anywhere to confirm it, and there is no volume behind the turn. The stock is coiled between a floor that keeps holding and a reversal read that hasn't proven itself. Resistance: 196.18-197.13 - the shelf right above price Key resistance: 198.47-199.89 - the band that rejected the last bounce Current price: 194.44 Support: 191.23 - the April floor, held three times Key support: 189.80 - the June sweep low Thesis line: 191.23 - the reversal lives or dies here Two paths from here: The floor reversal confirms. The daily flipped to a long read at 191.23 with the accel phase still showing, and a push back through 196.18 then 198.47 would validate the third defense of the floor as a bottom. This needs volume to arrive - Vol Elev sat at the very bottom of its range through the whole test, so the turn is unproven until buyers actually show up. The reversal fails and the floor breaks. The hourly long read is carrying an anti-signal (NR7), meaning the system is flagging its own bounce as suspect - the same setup that failed two days ago. A loss of 191.23 opens the 189.80 sweep low with nothing but air beneath it, and the daily accel phase resolves down instead of up. This is the third time 191.23 has held, and each hold makes the level more real - but the reversal read at it already failed once this week on the same anti-signal it is carrying again. The daily switching to long at the floor is the new element; it has not done that before. Volume is the tell. Without it, a coil on the floor is just a pause before the next test. Built with SYNTHESIS v3.3 | SOM / ACE / IMP / SYNTHESIS Study, not financial advice.